Table 1.
Patient demographics
|
ACT2 trial∗ |
All UK audit patients |
Two-phase conformal CRT in UK audit‡ |
IMRT as per guidance in UK audit‡ |
|
|---|---|---|---|---|
| (n = 246†) | (n = 242) | (n = 52) | (n = 157) | |
| Age (years), median (range) | 60 | 62 (29–90) | 59 (38–87) | 62 (29–88) |
| Age <65 years | 75% | 140 (58%) | 30 (58%) | 93 (59%) |
| Age ≥ 65 years | 25% | 102 (42%) | 22 (42%) | 64 (41%) |
| Gender | ||||
| Male | 38% | 64 (26%) | 11 (21%) | 47 (30%) |
| Female | 62% | 178 (74%) | 41 (79%) | 110 (70%) |
| Pre-treatment colostomy | ||||
| Yes | 13% | 38 (16%) | 11 (21%) | 24 (15%) |
| No | 87% | 204 (84%) | 41 (79%) | 133 (85%) |
| Pre-treatment PET/CT | ||||
| Yes | N/R | 95 (39%) | 19 (37%) | 65 (41%) |
| No | N/R | 147 (61%) | 33 (63%) | 92 (59%) |
| HIV status | ||||
| Positive | N/R | 8 (3%) | 1 (2%) | 7 (4%) |
| Negative | N/R | 84 (35%) | 11 (21%) | 67 (43%) |
| Not performed | N/R | 150 (62%) | 40 (77%) | 83 (53%) |
| Smoking status | ||||
| Current smoker | N/R | 58 (24%) | 21 (40%) | 38 (24%) |
| Ex-smoker (>6 months) | N/R | 46 (19%) | 9 (17%) | 30 (19%) |
| Never smoked | N/R | 95 (39%) | 16 (31%) | 60 (38%) |
| Do not know | N/R | 43 (18%) | 6 (12%) | 29 (18%) |
CRT, chemoradiotherapy; IMRT, intensity-modulated radiotherapy; PET/CT, positron emission tomography/computed tomography.
∗
Data from the arm receiving mitomycin concurrently and no maintenance chemotherapy.
†
Patients in the mitomycin, no maintenance were used for demographic comparison.
‡
Excluding patients without inguinal irradiation.